Dataset from A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
收藏NIAID Data Ecosystem2026-05-10 收录
下载链接：
https://doi.org/10.25934/PR00010141
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to evaluate the safety and efficacy of Mirikizumab in
participants with moderately to severely active ulcerative colitis (UC) who have had an
inadequate response to, loss of response, or intolerant to conventional or biologic therapy
for UC.
创建时间：
2026-01-19
